Prothena Corp Public price to sales ratio PRTA

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026: 7.7×
9-year median: 14.4×
Against its 9-year history: 23rd; percentile: 0 is its lowest day, 100 its highest
9-year range: 1.8× to 90.1×
Peer median: 1.5×

Prothena Corp Public's price to sales ratio is 7.7× as of Oct 23, 2026.

That is below its 9-year median of 14.4×, lower than on 77% of days in the last 9 years.

Over that time it ranged from 1.8× in May 2025 to 90.1× in Sep 2017.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

median 14.4×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.7×	7.3×	60.6×
2025	43.6×	1.8×	56.0×
2024	6.1×	3.8×	17.8×
2023	13.8×	12.6×	75.5×
2022	20.4×	5.5×	20.4×
2021	11.5×	10.2×	57.2×
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	19.3×	17.0×	63.1×
2017	52.5×	51.5×	90.1×
2016	n/m a value too high to mean anything
2015	107×	15.4×	107×

Against its peers

Companies in Drug Manufacturers - General nearest Prothena Corp Public's size, closest first, today.

Company	Price to sales ratio
PRTAProthena Corp Public	7.7×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
NATRNatures Sunshine Products	0.4×
ABUSArbutus Biopharma	4.6×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
Peer median	1.5×

Where Prothena Corp Public ranks

#97of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Prothena Corp Public

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.